Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Summary: Introduction: Crohn's disease (CD) and ulcerative colitis (UC) have a progressive course leading to hospitalisation and surgery. The ability of existing therapies to alter disease course is not clearly defined. Aim: To investigate the comparative efficacy of currently available inflammatory bowel disease (IBD) therapies to reduce hospitalisation and surgery. Methods: We conducted a systematic review in MEDLINE/PubMed for randomised controlled trials (RCT) published between January 1980 and May 2016 examining efficacy of biological or immunomodulator therapy in IBD. We performed direct comparisons of pooled proportions of hospitalisation and surgery. Pair‐wise comparisons using a random‐effects Bayesian network meta‐analysis were performed to assess comparative efficacy of different treatments. Results: We identified seven randomised controlled trials (5 CD; 2 UC) comparing three biologics and one immunomodulator with placebo. In CD, anti‐TNF biologics significantly reduced hospitalisation [Odds ratio (OR) 0.46, 95% confidence interval (CI) 0.36–0.60] and surgery (OR 0.23, 95% CI 0.13–0.42) compared to placebo. No statistically significant reduction was noted with azathioprine or vedolizumab. Azathioprine was inferior to both infliximab and adalimumab in preventing CD‐related hospitalisation (>97.5% probability). Anti‐TNF biologics significantly reduced hospitalisation (OR 0.48, 95% CI 0.29–0.80) and surgery (OR 0.67, 95% CI 0.46–0.97) in UC. There were no statistically significant differences in the pair‐wise comparisons between active treatments. Conclusions: In CD and UC, anti‐TNF biologics are efficacious in reducing the odds of hospitalisation by half and surgery by 33–77%. Azathioprine and vedolizumab were not associated with a similar improvement, but robust conclusions may be limited due to paucity of RCT s.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“10.(25) Separate analyses were carried out for CD and UC, and for hospitalisation and surgery.”
BackgroundThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.001 · Cited by 4,833
Self-citationFord Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,020
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60150-0 · Cited by 2,078
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationDias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
Peyrin-Biroulet, L., Loftus, E. V., Colombel, J.-F., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.579 · Cited by 1,047
Self-citationThe burden of inflammatory bowel disease in Europe
Burisch, J., Jess, T., Martinato, M., & Lakatos, P. L. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.01.010 · Cited by 961
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Frolkis, A. D., Dykeman, J., Negrón, M. E., deBruyn, J., Jette, N., Fiest, K. M., Frolkis, T., Barkema, H. W., Rioux, K. P., Panaccione, R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.041 · Cited by 892
Self-citationTurner, R. M., Davey, J., Clarke, M. J., Thompson, S. G., & Higgins, J. P. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys041 · Cited by 837 · cited 1×
“The prior was the previously published prior of Turner for semiobjective outcomes in trials of active treatment compared to placebo.(28) Sensitivity analyses repeated the”
ResultMucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S., & Rutgeerts, P. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20927 · Cited by 673 · cited 1×
“cantly reduced the need for surgery compared to episodic use,(43) with this effect more striking in those who achieved mucosal healing.(44) Timing of exposure to biologics may also be important in modifying natural his-”
BackgroundDirect Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
Kappelman, M. D., Rifas–Shiman, S. L., Porter, C. Q., Ollendorf, D. A., Sandler, R. S., Galanko, J. A., & Finkelstein, J. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.012 · Cited by 634 · cited 6×
“*Division of Gastroenterology, Alpert Medical School of Brown University, Providence, RI, USA.”
BackgroundInfluentialLichtenstein, G. R., Yan, S., Bala, M., Blank, M., & Sands, B. E. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.048 · Cited by 597 · cited 3×
“Most focused on clinical response or remission,47–52 and fewer on endoscopic outcomes.53 Some studies have used administrative datasets49, 54 or electronic health record (EHR)-linked cohorts52 and have suggested comparability of infliximab and adalimumab, though some clinical situations and outcomes favoured the super…”
BackgroundSchnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S., & Rutgeerts, P. (2009) · Gut · doi:10.1136/gut.2008.155812 · Cited by 535
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
Sandborn, W. J., Rutgeerts, P., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Lu, J., Horgan, K., Rachmilewitz, D., Hanauer, S. B., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.061 · Cited by 473 · cited 1×
“exposed and naive patients while the former trial included only anti-TNF naive patients.(34) Information on hospitalisation or surgery outcomes was not available for immunomodulators, golimumab or vedolizumab in UC.”
ResultBayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis
Ades, A. E., Sculpher, M., Sutton, A., Abrams, K., Cooper, N., Welton, N., & Lu, G. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624010-00001 · Cited by 420
D'Haens, G. R., Panaccione, R., Higgins, P. D. R., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S. B., Herfarth, H., Hommes, D. W., Kamm, M., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.392 · Cited by 409
Feagan, B. G., Panaccione, R., Sandborn, W. J., D'Haens, G. R., Schreiber, S., Rutgeerts, P. J., Loftus, E. V., Lomax, K. G., Yu, A. P., Wu, E. Q., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.069 · Cited by 374
Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease
Pariente, B., Mary, J.-Y., Danese, S., Chowers, Y., De Cruz, P., D’Haens, G., Loftus, E. V., Louis, E., Panés, J., Schölmerich, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.015 · Cited by 321
Dassopoulos, T., Sultan, S., Falck–Ytter, Y. T., Inadomi, J. M., & Hanauer, S. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.046 · Cited by 297
Hospitalisations and surgery in Crohn's disease
Bernstein, C. N., Loftus, E. V., Ng, S. C., Lakatos, P. L., & Moum, B. (2012) · Gut · doi:10.1136/gutjnl-2011-301397 · Cited by 294
Systematic review: the costs of ulcerative colitis in Western countries
COHEN, R. D., YU, A. P., WU, E. Q., XIE, J., MULANI, P. M., & CHAO, J. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04234.x · Cited by 289
Inflammatory Bowel Disease: A Canadian Burden of Illness Review
Rocchi, A., Benchimol, E. I., Bernstein, C. N., Bitton, A., Feagan, B., Panaccione, R., Glasgow, K. W., Fernandes, A., & Ghosh, S. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/984575 · Cited by 286
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285 · cited 1×
“Information on rates of surgery following active treatment or placebo was available in all trials 35 while one study did not provide data on CD-related hospitalisation.(35) All studies presented outcomes upon maintenance treatment though varied in whether an open-label arm was used for induction of remission and wheth…”
MethodThe Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort
Targownik, L. E., Singh, H., Nugent, Z., & Bernstein, C. N. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.127 · Cited by 280
Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., Kuenzig, E., Tomlinson, G., Siegel, C. A., Melmed, G. Y., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.011 · Cited by 276
Self-citationEarly Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
Panés, J., López–SanRomán, A., Bermejo, F., García–Sánchez, V., Esteve, M., Torres, Y., Domènech, E., Piqueras, M., Gomez–García, M., Gutiérrez, A., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.009 · Cited by 252
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
Behm, B. W., & Bickston, S. J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006893 · Cited by 239
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
Lawson, M. M., Thomas, A. G., & Akobeng, A. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005112.pub2 · Cited by 229
Stidham, R. W., Lee, T. C. H., Higgins, P. D. R., Deshpande, A. R., Sussman, D. A., Singal, A. G., Elmunzer, B. J., Saini, S. D., Vijan, S., & Waljee, A. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12749 · Cited by 201
Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study
Kaplan, G. G., Seow, C. H., Ghosh, S., Molodecky, N., Rezaie, A., Moran, G. W., Proulx, M.-C., Hubbard, J., MacLean, A., Buie, D., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.333 · Cited by 197
Self-citationPeyrin-Biroulet, L., & Lémann, M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04599.x · Cited by 196
Self-citationDanese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L., & Bonovas, S. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2403 · Cited by 195 · cited 3×
“Most focused on clinical response or remission,47–52 and fewer on endoscopic outcomes.53 Some studies have used administrative datasets49, 54 or electronic health record (EHR)-linked cohorts52 and have suggested comparability of infliximab and adalimumab, though some clinical situations and outcomes favoured the super…”
BackgroundSelf-citationThe costs of Crohn's disease in the United States and other Western countries: a systematic review
Peng Yu, A., Cabanilla, L. A., Qiong Wu, E., Mulani, P. M., & Chao, J. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260790 · Cited by 194
Nguyen, G. C., Tuskey, A. G., Dassopoulos, T., Harris, M. L., & Brant, S. R. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20250 · Cited by 161
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease
Akobeng, A. K., & Zachos, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003574.pub2 · Cited by 159
Stidham, R. W., Lee, T. C. H., Higgins, P. D. R., Deshpande, A. R., Sussman, D. A., Singal, A. G., Elmunzer, B. J., Saini, S. D., Vijan, S., & Waljee, A. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12644 · Cited by 159
Samuel, S., Ingle, S. B., Dhillon, S., Yadav, S., Harmsen, W. S., Zinsmeister, A. R., Tremaine, W. J., Sandborn, W. J., & Loftus, E. V. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31828c84c5 · Cited by 154
Singh, S. R. K., Al-Darmaki, A. K., Frolkis, A. D., Seow, C. H., Leung, Y., Novak, K. L., Ghosh, S., Eksteen, B., Panaccione, R., & Kaplan, G. G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.001 · Cited by 152
Self-citationTrends in Hospitalization Rates for Inflammatory Bowel Disease in the United States
Bewtra, M., Su, C. G., & Lewis, J. D. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.01.015 · Cited by 150
The Cost of Hospitalization in Crohn's Disease
Cohen, R. D., Larson, L. R., Roth, J., Becker, R. V., & Mummert, L. H. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01779.x · Cited by 147
Costa, J. N., Magro, F., Caldeira, D., Alarcão, J., Sousa, R., & Carneiro, A. V. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829936c2 · Cited by 146 · cited 1×
“pooled data from 27 eligible studies examining surgery or hospitalisation as an outcome with infliximab use.(46) In a pooled analysis including both RCTs and observational studies, infliximab was associated with a statistically significant reduction in surgery and hospitalisation with the magnitude ranging from 43% to…”
Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin‐Biroulet, L. (2010) · PubMed · Cited by 140
Self-citationBernstein, C. N., Ng, S. C., Lakatos, P. L., Moum, B., & Loftus, E. V. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f3bb · Cited by 117
Biologics in inflammatory bowel disease: what are the data?
Côté-Daigneault, J., Bouin, M., Lahaie, R. G., Colombel, J., & Poitras, P. (2015) · United European Gastroenterology Journal · doi:10.1177/2050640615590302 · Cited by 114
Feagan, B. G., Sandborn, W. J., Lazar, A., Thakkar, R. B., Huang, B., Reilly, N., Chen, N., Yang, M., Skup, M., Mulani, P. M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.09.032 · Cited by 108
Kestens, C., van Oijen, M. G. H., Mulder, C. L. J., Bodegraven, A. A. V., Dijkstra, G. D. H., de Jong, D., Ponsioen, C. Y., van Tuyl, B. A. C., Siersema, P. D., Fidder, H. H., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.012 · Cited by 99
Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study
Bernstein, C. N., Longobardi, T., Finlayson, G., & Blanchard, J. F. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21878 · Cited by 87
Ananthakrishnan, A. N., Issa, M., Beaulieu, D. B., Skaros, S., Knox, J. F., Lemke, K., Emmons, J. E., Lundeen, S. J., Otterson, M. F., & Binion, D. G. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20639 · Cited by 77
Self-citationMa, C., Beilman, C. L., Huang, V., Fedorak, D. K., Kroeker, K. I., Dieleman, L. A., Halloran, B. P., & Fedorak, R. N. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000679 · Cited by 77 · cited 1×
“tory; early use within 2 years of diagnosis may result in the greatest benefit.(45) Summarising this literature, Costa et al.”
BackgroundSingh, S., Garg, S. K., Pardi, D. S., Wang, Z., Murad, M. H., & Loftus, E. V. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.08.019 · Cited by 75
Singh, S., Heien, H. C., Sangaralingham, L. R., Schilz, S. R., Kappelman, M. D., Shah, N. D., & Loftus, E. V. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.03.038 · Cited by 69 · cited 1×
“of 3205 biological naive patients, infliximab but not adalimumab was associated with a lower risk of CD-related hospitalisation and surgery compared to certolizumab.(49) Other studies examining comparative effectiveness have adopted a network meta-analysis of randomised controlled trials, but focused on clinical respo…”
BackgroundComparative Effectiveness of Infliximab and Adalimumab in Crohnʼs Disease and Ulcerative Colitis
Ananthakrishnan, A. N., Cagan, A., Cai, T., Gainer, V. S., Shaw, S. Y., Savova, G., Churchill, S. E., Karlson, E. W., Kohane, I. S., Liao, K. P., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000754 · Cited by 60
Self-citationThorlund, K., Druyts, E., Toor, K., & Mills, E. J. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1024657 · Cited by 57
Lopez, A., Ford, A. C., Colombel, J., Reinisch, W., Sandborn, W. J., & Peyrin‐Biroulet, L. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.01.148 · Cited by 36
Self-citationSussman, D. A., Kubiliun, N. M., Mulani, P. M., Chao, J., Gillis, C. A. T., Yang, M., Lu, M., & Abreu, M. T. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22873 · Cited by 34
Abraham, N. S., Richardson, P., Castillo, D. L., & Kane, S. V. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.06.004 · Cited by 23 · cited 1×
“demonstrated a 50% reduction in surgery and hospitalisation with infliximab.(42) In an observational Belgian cohort, scheduled therapy with infliximab signifi-”
Background
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review
Jeong, D. Y., Kim, S., Son, M. J., Son, C. Y., Kim, J. Y., Kronbichler, A., Lee, K. H., & Shin, J. I. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.002 · Cited by 215
Metadata
- Authors
- Mao, E. J., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2016-11-10
- Volume
- 45
- Issue
- 1
- Pages
- 3-13
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2552690718
- Cited by
- 245
- References
- 60
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.